LabGenomics랩지노믹스
084650 · KOSDAQ · ₩084650 · 랩지노믹스
₩2,095▲ ₩85 (4.23%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩88B | ₩86B | ₩73B | ₩145B | ₩202B |
| Cost of sales | ₩58B | ₩54B | ₩41B | ₩48B | ₩77B |
| Gross profit | ₩31B | ₩31B | ₩32B | ₩97B | ₩125B |
| Operating income | −₩54B | −₩18B | −₩6.8B | ₩66B | ₩105B |
| Net income | −₩64B | −₩24B | −₩5.2B | ₩48B | ₩84B |
| Net income to shareholders | −₩64B | −₩24B | −₩4.7B | ₩48B | ₩84B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩230B | ₩296B | ₩313B | ₩251B | ₩204B |
| Current assets | ₩74B | ₩136B | ₩160B | ₩174B | ₩171B |
| Cash and equivalents | ₩6.8B | ₩25B | ₩42B | ₩99B | ₩71B |
| Total liabilities | ₩81B | ₩79B | ₩85B | ₩40B | ₩46B |
| Current liabilities | ₩60B | ₩76B | ₩65B | ₩20B | ₩41B |
| Borrowings | ₩64B | ₩50B | ₩50B | ₩21B | ₩5.3B |
| Total equity | ₩150B | ₩216B | ₩228B | ₩211B | ₩158B |
| Shareholders' equity | ₩150B | ₩216B | ₩228B | ₩209B | ₩158B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩31B | −₩13B | −₩3.8B | ₩69B | ₩65B |
| Capital spending | ₩1.1B | ₩3.7B | ₩5B | ₩38B | ₩14B |
| Free cash flow | −₩32B | −₩17B | −₩8.8B | ₩31B | ₩52B |
| Dividends paid | — | — | — | ₩3.3B | — |
Consolidated where available. Amounts in won.
Also known as: LabGenomics / 랩지노믹스 / 084650 / KRX:084650
Source: KRX statistical information